Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) saw strong trading volume on Wednesday. Approximately 685,107 shares were traded during trading, an increase of 9% from the previous session’s volume of 625,904 shares. The stock last traded at $16.0720 and had previously closed at $15.09.
More ArriVent BioPharma News
Here are the key news stories impacting ArriVent BioPharma this week:
- Positive Sentiment: Analysts retain buy ratings despite major target cuts. HC Wainwright lowered its price target from $47 to $27, Citigroup cut its target from $40 to $20, and JonesTrading reduced its target from $45 to $22. All three firms maintained “buy” ratings, suggesting they see potential value after the selloff. These targets imply substantial upside from recent trading levels.
- Neutral Sentiment: ArriVent is reviewing its strategy for firmonertinib. Following the Phase 3 failure, the company is evaluating its plans for the drug and the broader implications for its lung-cancer program. The outcome of that review could determine whether additional development or regulatory options remain available. ArriVent reviews firmonertinib plans after Phase III setback
- Negative Sentiment: The FURVENT Phase 3 trial missed its primary endpoint. Reports described the result as a failure of ArriVent’s lead asset in late-stage lung cancer, triggering a severe selloff and raising concerns about the company’s future commercial prospects. ArriVent BioPharma Shares Plunge 58% On Phase 3 FURVENT Failure ArriVent stock tumbles after trial misses primary endpoint
- Negative Sentiment: Shareholder and fraud investigations add legal overhang. Law firms have solicited investors who suffered significant losses and announced investigations into potential securities claims involving ArriVent. These announcements do not establish wrongdoing, but they may increase reputational, legal and financial risks. SBS Law ArriVent investor investigation
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on AVBP shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Jefferies Financial Group set a $18.00 price objective on ArriVent BioPharma in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a report on Tuesday, September 22nd. Guggenheim cut their target price on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Citigroup reduced their price target on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $27.44.
ArriVent BioPharma Stock Performance
The firm has a market capitalization of $823.97 million, a PE ratio of -4.62 and a beta of 1.34. The stock has a fifty day moving average price of $29.02 and a 200-day moving average price of $29.35.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). Research analysts expect that ArriVent BioPharma, Inc. will post -4.11 earnings per share for the current fiscal year.
Institutional Trading of ArriVent BioPharma
A number of institutional investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new position in shares of ArriVent BioPharma during the 2nd quarter worth approximately $59,000. Glenmede Trust Co. NA acquired a new stake in ArriVent BioPharma in the first quarter valued at approximately $209,000. The Manufacturers Life Insurance Company acquired a new stake in ArriVent BioPharma in the first quarter valued at approximately $209,000. Jupiter Topco LLC purchased a new position in ArriVent BioPharma in the second quarter worth $226,000. Finally, Arizona State Retirement System purchased a new position in ArriVent BioPharma in the second quarter worth $233,000. 9.48% of the stock is currently owned by institutional investors.
ArriVent BioPharma Company Profile
ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.
ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.
Featured Articles
- Five stocks we like better than ArriVent BioPharma
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
